Prognostic Effects of Imaging Ratios in Idiopathic Pulmonary Fibrosis - Pulmonology Advisor

Prognostic Effects of Imaging Ratios in Idiopathic Pulmonary Fibrosis - Pulmonology Advisor

Prognostic Effects of Imaging Ratios in Idiopathic Pulmonary Fibrosis - Pulmonology Advisor

Posted: 23 May 2019 02:00 AM PDT

Patients with idiopathic pulmonary fibrosis (IPF) who had a ratio of the diameter of the main pulmonary artery to that of the aorta (mPA/Ao) >1 on chest computed tomography (CT) had worse outcomes, according to the results of a recent study published in BMC Pulmonary Medicine.

The diameter of the mPA and Ao was measured by chest CT in patients after diagnosis of IPF. Associations between clinical outcomes and the ratio of the diameter of the mPA/Ao were examined retrospectively. The primary outcomes of interest were death and lung transplantation.

Among the 303 enrolled participants with IPF, 234 were men and 69 were women. The most common comorbidities were hypertension and diabetes mellitus. The median mPA/Ao ratio was 0.83. Of the 303 participants, 272 had an MPA/Ao ratio ≤1 whereas 31 had a ratio >1. The median main pulmonary artery diameter was 27.6 mm in the group with a ratio ≤1 and 32.9 mm in the group with a ratio >1. A lower body mass index; a higher score for sex, age, and physiologic variables; and a higher mPA/Ao ratio were significantly associated with a poor prognosis in patients with IPF.

The study authors wrote, "The results of this study indicate that an mPA/Ao ratio >1 is associated with worse outcomes, including death and lung transplantation, in patients with IPF."

Related Articles

They added, "We suggest that the diameters of the mPA and Ao should be measured on chest CT at the time of initial diagnosis of IPF and that patients found to have a higher mPA/Ao ratio be kept under close observation."

Reference

Choi JS, Lee SH, Leem AY, et al. Prognostic impact of the ratio of the main pulmonary artery to that of the aorta on chest computed tomography in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19(1):81.

Topics:

Idiopathic Pulmonary Fibrosis Restrictive Lung Disease

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more